News

Diabetes prevalence increases, but so does diabetes control

View on the News

Control isn’t enough

Yes, diabetes control has improved over the past decades. But not everyone is benefiting and, with the disease still on the rise, more needs to be done to stop it before it even starts.

Nearly 40% of patients are not achieving their glycemic target – especially minority groups, which continue to suffer more, and have more-serious, long-term diabetes complications. The "alarming increase" in both obesity and diabetes should give society pause, and inspire a national effort to interrupt both.

"We know from the Diabetes Prevention Program that an intensive lifestyle change effectively prevents or delays the onset of diabetes. Public policy should focus on increasing physical activity and optimizing and improving access to healthy food choices for adults as well as children.

"Although the Centers for Disease Control and Prevention is actively engaged in adapting the Diabetes Prevention Program model for the community, we need to ensure that adequate resources are allocated to target these issues at the individual, societal, and environmental levels. Indeed, the public and private sectors need to work closely together to tackle this immense problem."

Dr. Martin J. Abrahamson and Dr. Roeland J.W. Middelbeek of the Joslin Diabetes Center and Harvard Medical School, Boston, made these remarks in an accompanying editorial (Ann. Int. Med. 2014;160:572-3). Dr. Abrahamson has received fees from several pharmaceutical companies. Dr. Middelbeek had no relevant disclosures.


 

FROM THE ANNALS OF INTERNAL MEDICINE

The prevalence of diagnosed diabetes in the United States rose significantly from 1988 to 2010, jumping from 6% to 10%.

Prediabetes doubled in prevalence over the same time period, from 6% to 12%, Elizabeth Selvin, Ph.D., and her colleagues reported in the April 14 issue of the Annals of Internal Medicine (2014 [doi=10.7326/M13-2411]).

But while the prevalence of confirmed cases increased sharply, the prevalence of undiagnosed diabetes actually decreased slightly over the same time – meaning that almost all cases of diabetes in the United States are now being identified, wrote Dr. Selvin of Johns Hopkins University, Baltimore, and her coinvestigators. "At present, approximately 89% of all diabetes cases are diagnosed," the team wrote. "Furthermore, glycemic control among persons with diagnosed diabetes has improved, probably reflecting a combination of improvements in diagnosis, screening, and care."

©Tashatuvango/Thinkstockphotos.com

While confirmed cases of diabetes increased sharply, the prevalence of undiagnosed diabetes fell.

The researchers mined their data from two epochs of the National Health and Nutrition Examination Survey (1988-1994 and 1999-2010), comprising a total of almost 43,500 people. They assessed diabetes and prediabetes prevalence by both fasting plasma glucose and hemoglobin A1c (HbA1c) levels. They also looked at glucose control parameters and medication type in diagnosed patients. To investigate any association between diabetes and weight, they evaluated body mass index in the survey populations.

The mean prevalence of obesity in U.S. adults without diabetes jumped from 21% in the first epoch to 32% in the second. The change was similar among those with diabetes. The increases in both prediabetes and diabetes tracked the jump in obesity, leading the authors to conclude that obesity was a direct cause of disease.

Overall, the mean HbA1c level rose from 5.25% in the earliest years to 5.36% in 2010 – a small but significant increase. But the level was entirely stable in a subset of young adults who had normal body weight, blood pressure, and lipid levels (5%).

The prevalence of diabetes as measured by an HbA1c of at least 6.5% increased over the two epochs, from a low of 6% in the earliest years to 10% by the latest. The prevalence of prediabetes doubled (from 6% to 12%). "When applied to the 2010 U.S. Census, the total number of adults aged 20 [years] or older with total confirmed diabetes was 20.6 million," the authors wrote.

When the team used HbA1c levels to identify undiagnosed cases, they determined that 16% of cases in the earlier epoch were undiagnosed, compared with 11% in the later years – meaning that by 2010, 89% of U.S. cases were being identified.

As measured by an HbA1c of less than 7%, glycemic control improved from 51% to 59% over the study period. Among those who reported that they were taking diabetes medications, control increased from 40% to 55%.

Blacks and Hispanics shouldered a larger disease burden than did whites, the researchers wrote. "The prevalence ... in blacks was nearly double the prevalence in whites (15% vs. almost 9%). Mexican-Americans also had a greater prevalence of diabetes than whites (15.4% vs. 8.6%). Both ethnic minority groups had a greater prevalence of undiagnosed diabetes."

Control was also poorer, they said: Only 52% of blacks and 43% of Mexican-Americans had a calibrated HbA1c level less than 7%, compared with 57% of whites.

"The substantially greater prevalence of diabetes and prediabetes and poor rates of glycemic control (even among persons with medication-treated diabetes) in ethnic minority populations ... is particularly concerning because blacks and Mexican-Americans are also at greater risk for complications of diabetes, particularly retinopathy and kidney disease," the team noted.

The study was supported by the National Institute of Diabetes and Digestive and Kidney Diseases. Neither Dr. Selvin nor any of her coauthors had any financial declarations.

msullivan@frontlinemedcom.com

On Twitter @alz_gal

Recommended Reading

Nanotherapies make inroads in wound regeneration
MDedge Endocrinology
New cholesterol guidelines would add 13 million new statin users
MDedge Endocrinology
Adding HbA1c doesn’t improve CVD risk assessment
MDedge Endocrinology
Aleglitazar failed to reduce cardiovascular events in type 2 diabetes
MDedge Endocrinology
Bariatric surgery’s benefit persists in type 2 diabetes
MDedge Endocrinology
Post procedure clopidogrel cuts amputation rates
MDedge Endocrinology
FDA panel backs approval of inhaled insulin for type 1 and 2 diabetes
MDedge Endocrinology
Weekly exenatide shows long-term efficacy in type 2 diabetes
MDedge Endocrinology
Stress cardiac magnetic resonance feasible and prognostic in obese patients
MDedge Endocrinology
Newcomer misses noninferiority mark against established GLP-1 receptor agonist
MDedge Endocrinology